Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
multidisciplinary, NIH-funded research program at the interface of molecular imaging, antibody engineering, cancer biology, drug development, and translational oncology. Our laboratory develops next-generation
-
antibodies, antibody-drug conjugates, immunotherapies, targeted therapies, and engineered cell therapies. Discovering tumor-stromal, tumor-immune, and tumor-ECM programs that drive therapeutic resistance
-
both denaturing and native conditions. - Determine the Drug-to-Antibody Ratio (DAR) and characterize the Drug Load Distribution (DLD), when required. - Apply, when appropriate, bottom-up, middle-up
-
Skip to content Research engineer within antibody technology and cellular therapies Lund University Share: Facebook Twitter LinkedIn Email Application deadline September 10, 2026 Read more and apply
-
Research engineer within antibody technology and cellular therapies Login and apply Lunds universitet Lund University was founded in 1666 and is repeatedly ranked among the world’s top universities
-
with multidisciplinary teams to advance peptide- and antibody-based drug development programs Undertake other duties as assigned. 5.5 workday per week is required. Requirements a Ph.D. degree in
-
, writing, and communication abilities. Preference will be given to candidates with translational research experience in cancer immunology, antibody-based therapeutics, and/or antibody/protein engineering
-
Grade Level 11 Salary Range $27.00-45.70/hour Type of Position Staff Position Time Status Full-Time Required Education BS Click here for more information about equivalencies: https://hr.uky.edu
-
affiliations. Be You. The Global Health Discovery Collaboratory (GHDC) Antibody Dynamics team at the Duke University Center for Human Systems Immunology is seeking a detail-oriented scientist to fulfill a key
-
Biotechnology available within the project iSeRa-AI: Interactive Sequence Ranker (iSeRa) with improved candidate Antibody Identification (AI) through machine learning , Ref. 788 - iSeRa-AI_AF, financed by